Nuwellis Announces Board of Directors Transition
November 01 2023 - 8:00AM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused
on transforming the lives of people with fluid overload, today
announced the appointment of Dave McDonald and Archelle Georgiou,
MD, to its board of directors, effective November 1, 2023.
“With decades of experience and leadership in
their respective fields, we welcome Dave and Archelle to our board.
Dave’s significant experience in finance and strategy will provide
key insights to our board as we advance our growth and expansion
initiatives. In turn, our board will benefit from perspectives
gained from Archelle’s healthcare policy, clinical, and patient
education experience in bringing medical decisions closer to
patients and caregivers,” said Nestor Jaramillo Jr, President and
CEO of Nuwellis. “We look forward to our collaboration with Dave
and Archelle as we continue to drive market penetration of our
Aquadex® ultrafiltration therapy for patients with fluid overload
unresponsive to current standard of care.”
Mr. McDonald serves as Head of Life Science
Investment Banking at Lake Street Capital Markets, raising $6
billion in financing for clients since joining the firm. His
extensive industry and Capital Markets experience provide a unique
perspective to Lake Street clients. Immediately prior to joining
Lake Street, Mr. McDonald spent seven years in the oncology
industry, serving as a Senior Financial and Business Development
Executive for SillaJen Biotherapeutics, Delcath Systems, and
AngioDynamics. In addition, he has more than 35 years of Capital
Markets experience serving the needs of emerging growth companies
as a Healthcare Investment Banker, Equity Research Analyst, and
Investor with RBC Capital Markets, Craig-Hallum, Canaccord Genuity,
and American Express. Mr. McDonald received his BA in Economics
from St. Olaf College.
Dr. Georgiou is a physician with over 16 years
of experience in leadership positions in managed care, investment
banking, and medical device companies, including serving as Chief
Medical Officer and Senior Executive at UnitedHealth Group, and
currently serves as the Chair of the Board of Directors at
Children’s Hospital and Clinics of Minnesota and Executive in
Residence at the University of Minnesota's Carlson School of
Management. In addition to her business leadership experience, Dr.
Georgiou has produced and aired more than 2,000 news segments that
simplify complex healthcare information for viewers. As a
nationally recognized consumer advocate, Dr. Georgiou is passionate
about helping people make data-driven decisions. Dr. Georgiou has
been featured on CNN and Good Morning America, and has shared her
thought leadership at events hosted by the World Bank, Mayo Clinic,
Gallup, and AARP. Dr. Georgiou holds a degree from the Johns
Hopkins School of Medicine and was board-certified in Internal
Medicine.
In addition, Nuwellis announced that Jon
Salveson is stepping down from the Board after 10 years of
outstanding service. “During Jon’s tenure Nuwellis has benefitted
consistently from his judgment, counsel, and market insights. We
thank Jon for his service and recognize the numerous demands on his
time that make his continued Board service challenging,” said Mr.
Jaramillo. “I’m grateful for all the advice he provided during his
time on the Board.”
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology
company dedicated to transforming the lives of patients suffering
from fluid overload through science, collaboration, and innovation.
The company is focused on commercializing the Aquadex SmartFlow®
system for ultrafiltration therapy. Nuwellis is headquartered in
Minneapolis, Minnesota with a wholly owned subsidiary in Ireland.
For more information visit www.nuwellis.com or visit us on LinkedIn
or Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible, and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
CONTACTS
INVESTORS: Vivian CervantesGilmartin Group
ir@nuwellis.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Apr 2023 to Apr 2024